• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ICON plc

    5/7/21 10:40:33 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ICLR alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    ICON PLC


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    G4705A100


    (CUSIP Number)

    April 30, 2021


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. G4705A100

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Massachusetts Financial Services Company ("MFS")
    04-2747644
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    Not Applicable
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 5,163,666
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 5,304,231
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,304,231 shares of Common Stock consisting of shares beneficially owned by MFS and/or certain other non-reporting entities
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    Not Applicable
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.0%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    ICON PLC
    (b) Address of Issuer's Principal Executive Offices
    South County Business Park, Leopardstown, Dublin 18, Ireland
    Item 2.
    (a) Name of Person Filing
    Massachusetts Financial Services Company
    (b) Address of Principal Business Office or, if None, Residence
    111 Huntington Avenue, Boston, MA 02199
    (c) Citizenship
    Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    G4705A100
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    5,304,231 shares of Common Stock consisting of shares beneficially owned by MFS and/or certain other non-reporting entities
    (b) Percent of Class:
    10.0%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 5,163,666
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 5,304,231
    (iv) shared power to dispose or to direct the disposition of 0
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Massachusetts Financial Services Company
    By: /s/ Robert R. Flaherty
    Date: May 07, 2021
    Name: Robert R. Flaherty
    Title: Vice President

    Get the next $ICLR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICLR

    DatePrice TargetRatingAnalyst
    4/29/2025$150.00Overweight → Neutral
    Analyst
    4/14/2025$157.00Buy → Hold
    TD Cowen
    4/10/2025$165.00Overweight → Equal Weight
    Barclays
    3/21/2025$250.00 → $200.00Buy → Neutral
    Goldman
    1/7/2025$263.00Outperform
    RBC Capital Mkts
    10/24/2024$340.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Neutral
    Redburn Atlantic
    9/18/2024$379.00Outperform
    Leerink Partners
    More analyst ratings

    $ICLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ICON plc downgraded by Analyst with a new price target

      Analyst downgraded ICON plc from Overweight to Neutral and set a new price target of $150.00

      4/29/25 8:06:12 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by TD Cowen with a new price target

      TD Cowen downgraded ICON plc from Buy to Hold and set a new price target of $157.00

      4/14/25 8:13:29 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by Barclays with a new price target

      Barclays downgraded ICON plc from Overweight to Equal Weight and set a new price target of $165.00

      4/10/25 8:49:19 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Leadership Updates

    Live Leadership Updates

    See more
    • Anne Whitaker Appointed as Non-Executive Director

      MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

      4/3/25 6:13:56 PM ET
      $ICLR
      $TLX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • ICON Announces Appointment of Chief Operating Officer

      ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to

      12/18/24 7:00:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON Announces Appointment of New Chief Financial Officer

      ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes

      8/14/24 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    SEC Filings

    See more
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      6/18/25 5:14:28 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      6/11/25 4:18:21 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      5/27/25 8:34:09 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ICON plc to Present at the William Blair 45th Annual Growth Stock Conference

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025 at 10.40 am CT. Any changes to this event and links to the live webcast (where available) will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public he

      5/27/25 8:30:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON releases its ICON Cares 2024 Report

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its ICON Cares program. In recognition of its efforts in 2024, ICON received a score of 72/100 from EcoVadis, a leading provider of business sustainability ratings, an increase of two points on the previous score, earning ICON a silver medal. ICON also achieved a B- score on its CDP Climate Change response. Most recently, ICON has been named by TIME magazine as one the World's Best Companies in Sustainable Growth 202

      5/19/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% o

      5/7/25 7:27:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Financials

    Live finance-specific insights

    See more
    • ICON Reports First Quarter 2025 Results

      Highlights Net business wins in the quarter of $2,022 million; a net book to bill in the quarter of 1.01. Closing backlog of $24.7 billion, an increase of 0.3% on quarter four 2024 and 6.0% on quarter one 2024. Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue. GAAP net income for the quarter was $154.2 million or $1.90 per diluted share. Quarter one adjusted net income was $258.3 million or $3.19 per diluted share. Net debt was $2.9 billion at March 31, 2025 with a net debt to adjusted EBITDA ratio of 1.7x. $250.0 million worth of stock repurchased in quarter one at an average price of $184. Updating full-year 20

      4/30/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc Schedules First Quarter 2025 Earnings Conference Call

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, April 30, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 1, 2025 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading

      3/31/25 6:30:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON Reports Fourth Quarter and Full Year 2024 Results

      Highlights Net business wins in the quarter of $2,413 million; a net book to bill in the quarter of 1.18. Full year net business wins of $9,974 million; a net book to bill of 1.20. Closing backlog of $24.7 billion, an increase of 1.4% on quarter three 2024 and 8.3% on quarter four 2023. Quarter four revenue of $2,041.1 million, representing a decrease of 1.2% on prior year revenue. Full year revenue of $8,282 million representing a year on year increase of 2.0%. Quarter four adjusted EBITDA of $422.6 million or 20.7% of revenue, an increase of 0.9% on quarter three 2024. Full year adjusted EBITDA of $1,735.8 million or 21.0% of revenue, representing a year on year increase of 2.5%.

      2/19/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ICON plc

      SC 13G/A - ICON PLC (0001060955) (Subject)

      11/12/24 11:54:03 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by ICON plc (Amendment)

      SC 13G/A - ICON PLC (0001060955) (Subject)

      2/9/24 11:49:03 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by ICON plc (Amendment)

      SC 13G/A - ICON PLC (0001060955) (Subject)

      1/30/24 12:11:57 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care